Positive data reported from phase III DAPA-CKD clinical trial of dapagliflozin in end stage kidney disease

RCT evaluating 10mg dose compared to placebo, in addition to standard of care, in 4304 patients with CKD stages 2-4 demonstrated statistically significant effect on composite of worsening of renal function or risk of death, onset of end stage kidney disease or CV or renal death.


Biospace Inc.